Inflammation-induced lung fibrosis represents a common final pathway of various pulmonary disorders, such as the adult respiratory distress syndrome or interstitial lung diseases. Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with a high mortality rate and very limited therapeutic options (1, 2) . The etiology and pathogenesis of IPF are not completely understood (2) . Release of profibrotic cytokines and abnormal fibroblast proliferation contributes to tissue remodeling and progressive lung fibrosis. Intratracheal instillation of bleomycin (BLM) triggers an IPF-like disease in mice (3) . BLM instillation results in oxidative damage to the DNA of the alveolar epithelium, promoting the recruitment and expansion of alveolar macrophages (AMs), neutrophils, and lymphocytes. This inflammatory process triggers fibroblast proliferation and results in excessive collagen deposition progressing to pulmonary fibrosis (4) .
Cell-based therapies might become a promising tool for the modulation of inflammatory processes and regeneration of damaged tissues (5) . The lung exhibits a complex architecture with some regenerative capacity. Anatomically, the lung is divided in three main regions: proximal airways, distal airways, and alveolar space, which is composed of alveolar type I cells (.95%) and type II cells (,5%). The current view is that any of these regions contains a stem cell niche able to renew the local epithelial cell population after injury (6) (7) (8) (9) (10) . Concerning the alveolar epithelium, type II pneumocytes are regarded as a stem cell-like population because of their capacity to proliferate and differentiate into type I cells after local injury (11) . Unfortunately, type II pneumocytes are not sufficient to abrogate or prevent the progression of pulmonary disorders (12) , suggesting that an exogenous source is necessary.
Bone marrow shows high plasticity and is believed to contribute to the homeostasis and repair of nonhematopoietic organs (13, 14) . Recent data suggest that bone marrow-derived cells are involved in lung regeneration (15) (16) (17) . Furthermore, it appears that the extent of tissue injury defines the capacity of bone marrow-derived cells to regenerate the pulmonary epithelium (15, 16, (18) (19) (20) .
Prominin-1/CD133 is a recognized marker of hematopoietic stem cells and committed progenitors (21, 22) and is also AT A GLANCE COMMENTARY Scientific Knowledge on the Subject Lung injury activates tissue resident cells with regenerative capacity. Such cells might become of interest for designing novel cell-based therapies.
expressed on adult epithelial cells (23, 24) . Several lines of evidence suggest that prominin-1/CD133 1 progenitor cells might be beneficial for treatment of several pathological disorders, including leukemia and cardiac and hepatic malignancies (25) (26) (27) (28) .
Herein we describe the expansion of high numbers of bone marrow-derived prominin-1/CD133 1 epithelial progenitor cells (PEPs) from adult mouse lungs. These PEPs combined immunomodulatory and regenerative capacities and protected mice from the development of BLM-induced pulmonary fibrosis in a nitric oxide (NO)-dependent manner.
MATERIALS AND METHODS

Mice
C57Bl/6 mice and C57Bl/6-green fluorescent protein (GFP) transgenic mice (GFP under the control of b-actin promoter) were purchased from Jackson Laboratory (Bar Harbor, ME) and housed in a specific pathogen-free environment. Inducible nitric oxide synthase (iNOS) 2/2 C57Bl/ 6 mice were kindly provided by Dr. Adrian J. Hobbs, Wolfson Institute for Biomedical Research, University College London, London. All animal experiments were conducted in accordance with institutional guidelines and Swiss federal law and were approved by the local authorities.
Generation of Bone Marrow Chimera
Five-to 7-week-old C57Bl/6 mice were lethally irradiated with two doses of 6.5 Gy using a Gammatron (Co-60) system and reconstituted with 2 3 10 7 donor bone marrow cells from C57Bl/6 GFP mice.
Bleomycin-Induced Lung Fibrosis
Seven-to 9-week-old male C57Bl/6 mice were anesthetized and intratracheally injected with 0.05 U/mouse of bleomycin (BLM) (Blenoxane, Axxora-Alexis, San Diego, CA) dissolved in 50 ml of sterile phosphate buffered saline (PBS). Control animals received the same volume of PBS. Two hours after PBS/BLM instillation, the animals received intratracheally either 2 3 10 5 PEPs resuspended in 50 ml of PBS or PBS alone.
Expansion of Prominin-1 1 Epithelial Progenitor Cells
Lungs of 7-to 9-week-old C57Bl/6 mice were perfused with 5 to 10 ml of ice-cold PBS, excised, separated from the trachea and the main bronchi, manually dissected into small pieces, and digested for 90 minutes at 378C in 15 ml of GKN (11 mM D-glucose, 5.5 mM KCl, 137 mM NaCl, 25 mM Na 2 HPO 4 , 5.5 NaH 2 PO 4 ÁH 2 O) containing 10% fetal calf serum (FCS), 1.8 mg/ml collagenase type 4, and 0.1 mg/ml DNase I. The cell suspension was filtered through 70-mm nylon mesh and washed with GKN containing 10% FCS. Cells were resuspended in IMDM (Iscove's Modified Dulbecco's Medium, Gibco, Grand Island, NY) containing 2% FCS, 100 mM b-mercaptoethanol (Gibco), 100 U of penicillin, and 100 mg of streptomycin/ml (Pen/Strep, Gibco), 2mM L-glutamine, 25 mM N-2-hydroxyethylpiperazine -N9-ethane sulfonic acid, and plated at 5 3 10 6 cells into 6-cm diameter tissue culture dishes. Culture of lung homogenates gave rise to two main populations consisting of a round cell population and a fibroblast-like cell population that worked as a feeder layer. Cells were incubated at 378C in a humidified atmosphere containing 5% CO 2 . The medium was changed two to three times a week. Nonadherent cells were removed 48 to 72 hours after plating. After 3 to 4 weeks cells were removed, washed, stained for 30 minutes at 48C with an anti-prominin-1-PE antibody (eBiosciences, San Diego, CA) (1:200) and isolated using anti-PE antibodies coupled to magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) (purity . 95%). For alveolar epithelial cell differentiation, PEPs were cultured on 0.2% gelatin-coated cover slips in the presence of modified Small Airway Growth Medium (SAGM) (29) consisting of a basal medium (Small Airway Basal Medium, Cambrex, East Rutherford, NJ) supplemented with 0.5 mg/ml bovine serum albumin, 0.5% FCS, insulin/transferrin/selenium (ITS) supplement, 30 mg/ml bovine pituitary extract, 0.5 mg/ml epinephrine, 6.5 ng/ml triiodothyronine, 0.1 ng/ml retinoic acid, 0.5 mg/ml hydrocortisone, and 1 ng/ml epidermal growth factor (EGF).
Fluorescence-Activated Cell Sorting
Cells were filtered through 70-mm nylon mesh, stained for 30 minutes on ice with the appropriate antibodies, and analyzed on a CyAN ADP (Dako-Cytomation, Carpinteria, CA) using FlowJo 8. 
Histology
Animals were killed on selected days after BLM instillation. Lungs were perfused, removed, fixed in 4% formaldehyde, and stained with hematoxylin and eosin and/or Masson's trichrome stain to visualize collagen depositions.
Bronchoalveolar Lavage
Mice were killed by intra-peritoneal Pentothal injections (Abbott, North Chicago, IL). The trachea was exposed and bronchoalveolar lavage fluid (BALF) was obtained by three instillations of 1 ml of icecold PBS. BALF was centrifuged, resuspended in 100 ml of PBS, cytospun onto slides, Diff-Quik stained (according to the manufacturer's protocol), and analyzed under a light microscope.
Blood Collection
Blood was collected via the inferior vena cava after opening the body cavity. A 1-ml syringe containing EDTA was used to bleed the mice. Cells were separated from erythrocytes using Lympholyte-M (Cedarlane Laboratories Ltd, Hornby, Canada) according to the manufacturer's instructions.
Alveolar Macrophages Isolation
BALFs from several mice were pooled and centrifuged at 300 3 g for 10 minutes. The resulting pellet was resuspended in RPMI-1640 medium supplemented with 10% FCS and incubated for 1 hour at room temperature on 10-cm diameter plastic dishes. Nonadherent cells were washed off with PBS and the adherent macrophages were collected.
Coculture Experiments
PEPs were purified using magnetic beads, irradiated (2,000 rad) and cultured in 96-well plates in the presence of alveolar macrophages at a ratio of 1:2. Cells were stimulated for 24 hours with LPS (0.1 mg/ml) and IFN-g (50 ng/ml). [ 3 H]Thymidine incorporation was measured as a readout for proliferation. Nitrite (NO 2 2 ) levels reflecting NO production in culture supernatants were assessed using the Griess Reagent System (Promega, Madison, WI).
Reverse Transcription and Real-Time Polymerase Chain Reaction
RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) from total lung tissue according to the manufacturer's recommendations. First strand cDNA synthesis was performed as follows: RNA (2 mg) was incubated with oligo(dT) 18 Table 1 . RT-PCR was performed using a 7,500 Fast RT-PCR System (Applied Biosystems, Foster City, CA) in the presence of SYBR-green (Applied Biosystems); glyceraldehyde-3-phosphate dehydrogenase was used as internal control. Amplification conditions were as follows: 508C (2 min); 958C (10 min); 958C (15 s), 608C (1 min), 40 repetitions. Specificity of each reaction was ascertained by performing the Melt procedure (60-958C; 18C/15 s) after completion of the amplification protocol, according to the manufacturer's instructions. Relative gene expression was analyzed using the 2 2DDCt method.
Statistics
Normally distributed data, such as proliferation responses and cytokine levels, were compared using the Student t test. Statistical analysis was conducted using Prism 4 software (GraphPad Software). P , 0.05 was considered to be statistically significant.
RESULTS
Expansion of Prominin-1 1 Epithelial Progenitor Cells
Several lines of evidence suggest that activation of tissue resident progenitor cells represents an injury-triggered process (9, 10) . Thus, we hypothesized that dissection of pulmonary tissue creates a specific ''injured'' microenvironment that can promote the expansion of progenitor cells with a lung-specific differentiation capacity. In fact, the culture of lung homogenates gave rise to a population of small, round, semi-attached cells, growing on a feeder layer ( Figures 1A and 1B ). FACS analysis revealed that the vast majority of these round cells expressed prominin-1, stem cell antigen (Sca-1) ( Figure 1E ), ckit (CD117) ( Figure 1F ), chemokine receptor type 4 (CXCR4) ( Figure 1G ), as well as the hematopoietic antigen CD45 ( Figure  1H ), but not CD34 ( Figure 1I ). PEPs were then purified by cell sorting and further analyzed. RT-PCR revealed that PEPs were negative for bronchial (Clara Cell 10-kd protein, CC10), alveolar type I (aquaporin-5, AQP5), alveolar type II (surfactant protein-C, SP-C), and epithelial (E-cadherin and keratin 5, K5) genes, but expressed genes characteristic for stem and progenitor cells (Islet-1, Nanog, but not Oct4) ( Figure 1D ). Of note, sorted prominin-1 1 /GFP 1 cells do not grow on feeder layers from other organs or on embryonic fibroblasts (i.e., 3T3 cells) (see Figure E1 in the online supplement).
All prominin-1 1 cells coexpressed hematopoietic markers. To confirm the bone marrow origin of these cells, mice were lethally irradiated and reconstituted with bone marrow cells from GFP 1 transgenic mice. Three weeks after bone marrow transplantation, we dissected lung tissues and expanded prominin-1 1 lung-derived progenitors as described. As illustrated in Figure 1C , nearly all prominin-1 1 cells were GFP positive ( Figure 1C ), indicating clearly that PEPs are of bone marrow origin.
Prominin-1 1 Epithelial Progenitor Cells Differentiate into Alveolar Type II Epithelial Cells
We next addressed the potential of prominin-1 1 progenitors to differentiate into an epithelial phenotype. To induce alveolar epithelial differentiation, sorted PEPs were cultured for 2 weeks in modified SAGM (29) . Immunofluorescence microscopy showed that PEPs acquired the expression of surfactant protein-C (SP-C) ( Figure 2B ), which is specific for pulmonary type II cells, but lose the expression of prominin-1 ( Figure E2 ). RT-PCR confirmed the expression of SP-C, but not of CC10 and AQP5, which are characteristic for bronchial and alveolar type I epithelial cells, respectively ( Figure 2D ). GFP 1 PEPs expanded from lungs of chimeric mice exhibited a similar capacity to differentiate into type II epithelial cells in vitro ( Figure 2C ).
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into C57Bl/6 mice after BLM instillation. At Day 1 after delivery, GFP 1 cells were detected in the alveolar walls only and were negative for SP-C (Figures 2E22G). In contrast, 7 days after delivery most GFP 1 cells expressed SP-C ( Figures  2H-2J ). GFP 1 /SP-C 1 cells corresponded to 1.71 6 0.43% out of the total amount of SP-C 1 cells. Importantly, GFP 1 cells did not engraft into the alveolar epithelium of unchallenged animals (data not shown).
Taken together, these findings clearly demonstrate that PEPs have the capacity to differentiate into type II pneumocytes in vitro and in vivo.
Identification of Two Distinct Prominin-1 1 Cell Populations in the Adult Mouse Lung
We next addressed the presence of prominin-1 1 cells within the healthy mouse lung. Distal airways were isolated from adult Figure 3B ); prominin-1 1 cells were then stained for CD45 antibody. Analysis of samples showed that among the prominin-1 1 subset, 6.82 6 0.31% were coexpressing CD45 ( Figure 3C) . Collectively, the percentage of prominin-1 1 /CD45 1 cells in the adult mouse lungs corresponds to 0.71 6 0.08%. In addition, staining of frozen sections confirmed the presence of two different cell phenotypes in the adult lung. In fact, rare, single round prominin-1 1 cells were detected in the alveolar epithelium ( Figure 3D, asterisk) Figure 3D , arrows) (see Figure E3 for negative control).
Next, we performed further stains on frozen sections to characterize the two prominin-1-expressing populations. As shown, round prominin-1 1 cells were detectable only in the alveolar epithelium, but they were all negative for type IIspecific marker SP-C (Figures 3E-3G ) and for type I marker AQP5 (data not shown). In addition they were all coexpressing CD45 (Figures 3H-3J) . The second subset of prominin-1 1 cells was found in the bronchial epithelium and the expression was restricted on the apical surface ( Figure 3K ). As shown in Figures 3L-3M , these cells were all coexpressing b-tubulin IV, which stains for cilia and is specifically expressed on bronchial epithelial cells.
To confirm that epithelial progenitor cells specifically expanded from the hematopoietic prominin-1 1 population, we sorted ex vivo prominin-1 1 /GFP 1 cells from chimeric mice and cultured them on a lung tissue-derived feeder layer. Up to 10 GFP 1 cells were cultured with 5 3 10 5 feeder layer cells (Figures 4A-4C ). Single prominin-1 1 /GFP 1 cells expanded and gave rise to colonies ( Figure 4D) . Transfer of prominin-1 1 /GFP 1 cells into SAGM resulted in their differentiation into type II alveolar epithelial-like cells expressing SP-C ( Figures  4E-4G ). Prominin-1 1 /GFP 1 cells sorted from blood did not expand and did not give rise to colonies ( Figure E4 ).
Prominin-1 1 Epithelial Progenitor Cells Protect from Bleomycin-induced Pulmonary Fibrosis
At Day 7 after intrapulmonary delivery of GFP 1 PEPs into BLM-challenged mice ( Figures 2E-2K) , alterations in the alveolar epithelial architecture, typically affected after BLM treatment, were not evident. Given this observation, we set out to specifically address the reparative and protective capacity of PEPs in the BLM model. Figures 5A, 5D , and 5G illustrate the architecture of the alveolar epithelium in unchallenged, PBSinjected mice (control). In BLM-challenged mice intratracheally injected with PBS the alveolar epithelium was massively damaged with extensive collagen deposition and progressive fibrosis ( Figures 5B, 5E, 5H ). In contrast, intratracheal delivery of PEPs to BLM-challenged mice resulted in the preservation of an almost completely normal architecture of the alveolar epithelium for up to at least 21 days ( Figures 5C, 5F , 5I). Administration of PEPs into BLM-challenged mice also protected from progressive loss of body weight ( Figure 5J) .
Importantly, whereas BALF samples taken at Days 3 and 7 from BLM-treated control mice injected with PBS only had increased numbers of total cells, samples taken from BLMchallenged mice injected with PEPs did not ( Figure 5K and Table 2 ). RT-PCR analysis of Day 7 lung samples from PEPtreated mice showed no upregulation of IL-4, IL-6, IL-13, and TNF-a, nor of the chemokines KC, CCL2, MIP-1a, and MCP-5 mediating inflammatory cell recruitment (30, 31) (Figure 5L ). Profibrotic genes, such as TGF-b1, and genes of cytokines mediating fibrocytes recruitment, such as SDF-1a or CCL21 (32, 33) , were also not upregulated in PEP-treated animals at Day 21 ( Figure 5M) . Accordingly, FACS analysis on blood samples revealed that the number of circulating fibrocytes (CD45 1 /Col I 1 /CXCR4 1 ) did not increase in mice that had received PEPs ( Figure E5) .
Similarly, mice that received bleomycin intraperitoneally followed by intratracheal injections of PEPs, showed markedly less fibrosis and displayed significant reduction of the collagen content in the lung. Control mice treated with PBS on the other hand developed significantly more lesions and showed higher collagen deposition and more thickened epithelium ( Figure  E6 ).
Taken together, these results indicate that intratracheal administration of PEPs specifically prevents the recruitment of inflammatory cells, abnormal extracellular matrix remodeling, and pulmonary fibrosis in BLM-challenged mice.
Prominin-1 1 Epithelial Progenitor Cells Suppress Alveolar Macrophage Proliferation
To specifically address the mechanism whereby PEPs mediate suppression of BLM-induced fibrosis, we focused on the early stages of disease development in this injury model. We compared the expression of various pro-and antiinflammatory genes in Day 1 lungs of control PBS-treated mice, and BLMchallenged mice treated or not with PEPs ( Figure 6A ). Lungs of PEPs-treated mice did not show an upregulation of IL-4 and IL-13. Importantly, lungs of PEPs-treated mice also did not display upregulation of KC/CXCL1 and CCL2, chemokines mainly produced by macrophages, which are considered as key players for the onset of pulmonary fibrosis in the BLM-induced injury model (31) . However, BLM-challenged mice injected with PEPs showed significant upregulation of iNOS ( Figure 6A ). Current evidence suggests a regulatory effect of NO in many cell types (34-37) and a protective role in various lung disease models (38) (39) (40) . To clarify whether PEPs or AMs were major NO producers, and to specifically assess effects of PEPs on the proliferation of AMs, we performed coculture experiments. As illustrated in Figure 6B , the proliferation of AMs was dramatically reduced when cultured in the presence of PEPs. PEPsinduced suppression of AM proliferation required cell-to-cell contact between AMs and PEPs ( Figure 6D ). Compared with individual cultures of AMs or PEPs, NO release was markedly increased in the supernatant of AM and PEPs cocultures ( Figure 6C ). To evaluate the role of NO in growth arrest, we first assessed proliferation responses in the presence of the nonspecific NO synthase inhibitor L-NAME. As shown in Figure 6E , addition of L-NAME neutralized the effect of PEPs and restored AM proliferation capacity. We next expanded PEPs from iNOS-deficient mice and cocultured them with AMs. iNOS 2/2 PEPs did not suppress the proliferation of AMs in vitro ( Figure 6B ). NO levels increased only in cocultures of AMs with iNOS 1/1 , but not iNOS 2/2 PEPs (Figure 6C ), confirming that NO was produced specifically by PEPs. It is noteworthy that NO production did not differ between irradiated and nonirradiated PEPs (data not shown). Taken together, our findings suggest that PEPs directly inhibit the proliferation of AMs, which are critical for disease development in the BLMinduced lung injury model (31) . In addition, our in vitro data argue for a critical role of NO in regulation of AM proliferation.
Nitric Oxide Mediates the Protective Effects of Prominin-1 1 Epithelial Progenitor Cells
To address the role of iNOS and NO in the PEPs-mediated suppression of BLM-induced lung injury in vivo, we injected BLMchallenged mice with either iNOS 1/1 or iNOS 2/2 prominin-1 1 cells. BALF was collected at Day 7. The number of total cells in BALF from mice injected with iNOS 1/1 PEPs was comparable to the BALF of mice challenged with PBS only ( Figure 7A ). However, BALF from BLM-challenged mice injected with iNOS 2/2 PEPs contained a markedly increased number of total cells. Hematoxylin and eosin and Masson's Trichrome staining of lung sections from iNOS 2/2 PEPs-treated animals revealed the presence of inflammatory foci and collagen deposition ( Figures 7E,  7I, 7M ), comparable to that in lungs from BLM-challenged mice ( Figures 7C, 7G, 7K) . Importantly, mice that received other NOproducing cells, such as bone marrow-derived macrophages or bone marrow-derived dendritic cells, were not protected from pulmonary fibrosis ( Figure E7 ).
In conclusion, bone marrow-derived PEPs expanded from mouse lungs possess regenerative capacity and striking antiinflammatory properties, and protect BLM-treated mice from pulmonary fibrosis in an NO-dependent manner.
DISCUSSION
This study has identified a population of prominin-1/CD133 1 bone marrow-derived epithelial progenitors with antiinflamma- tory properties and regenerative capacity from adult mouse lungs.
In support of the hypothesis that lung injury exceeding a certain threshold is necessary to activate stem/progenitor cell expansion, we found that dissection of pulmonary tissue resulted in the expansion of a small, round, undifferentiated population of prominin-1 1 cells growing on a feeder layer. Recent studies have shown the presence of stem cell populations within lungs (9, 41) . Our sorted prominin-1 1 /CD45 1 cells were negative for SP-C and CC10. Accordingly, they represent a distinct subset from bronchioalveolar stem cells (9) . Furthermore, our PEPs were of hematopoietic origin and clearly expressed a phenotype different from the bronchioalveolar stem cells and lung side population mesenchymal stem cells described by Summer and colleagues (41) .
We have demonstrated that the healthy mouse lungs displayed two distinct prominin-1 1 cell phenotypes. We identified for the first time the presence of a population of prominin-1 1 / CD45 1 cells within the adult mouse lung. On the other hand, the majority of prominin-1 1 cells belonged to the bronchial epithelial ciliated population. Prominin-1/CD133 expression has been already found on different adult epithelial cells (22) . Our findings are consistent with recent work of Shmelkov and collaborators (24) demonstrating the presence of prominin-1 1 cells along the bronchial epithelium. Notably, prominin-1 1 / GFP 1 cells sorted from chimeric lungs expanded only in the presence of a feeder layer from GFP-negative cultures, but not in presence of other feeder layers including embryonic fibroblasts. This observation suggests that expansion of bone marrow-derived PEPs is specifically triggered by lung-derived cells. On the other hand, it was not possible to expand in vitro prominin-1 1 cells isolated from mouse blood under the same conditions. These records clearly exclude that PEPs expanded from lungs could represent a residual of blood cells.
PEPs differentiated in vitro into type II epithelial cells. Based on their expression of type II alveolar specific gene SP-C, but not bronchial epithelial CC10, PEPs may represent a specific early committed alveolar progenitor population. In support of this notion, intratracheal injection of PEPs in BLMchallenged mice resulted in straight differentiation toward a type II epithelial phenotype. These data underscore the striking regenerative potential of PEPs in vivo. It is significant that PEPs engrafted into the alveolar walls of the lungs of BLMchallenged animals only. These findings support the view that tissue injury is necessary to create a specific microenvironment that promotes engraftment and subsequent differentiation of PEPs. Our data are consistent with other studies that have demonstrated the occurrence of tissue-specific differentiation of engrafted bone marrow cells only in challenged animals (17, 19) . Accumulating evidence supports a beneficial role of administered stem or precursor cells in several injury models (5, 28, (42) (43) (44) (45) . Here we have demonstrated that intratracheal injection of PEPs in the BLM-injury model resulted in complete protection from pulmonary fibrosis. Other studies have shown that injection of bone marrow-derived stem cells can ameliorate BLM-induced lung fibrosis (18, 19) . In line with these studies, we found that beneficial effects occur only when PEPs are injected during the early phases after BLM instillation. Intrapulmonary delivery of mesenchymal stem cells has been shown to attenuate the effects of pulmonary injury in different animal models when administered at early stages (46, 47) , indicating that stem cells of hematopoietic and mesenchymal origin share similar immunological properties. It remains to be established whether bone marrow-derived stem cells might exert a similar protective potential in reverting BLM-induced effects at the late stages of fibrosis. In the presence of profibrotic cytokines and massive damage to the whole alveolar epithelium, a higher number of cells might be required to exert an adequate response.
Our study also demonstrates that PEPs exerted an antiinflammatory effect in vivo and suppressed AM proliferation in vitro. Baran and colleagues (31) have shown that the presence of macrophages is crucial for development of BLM-induced fibrosis. The fundamental role of AM in the context of lung injury has been similarly noted in other studies (48, 49) . We found that injection of PEPs suppressed the production of cytokines secreted by macrophages, such as KC/CXCL1, which might explain the lack of neutrophils recruitment to the lungs of PEPs-treated BLM-challenged mice. In addition, no upregulation of SDF-1a was found in lungs of the PEPs-treated mice. Lack of SDF-1a upregulation, as well as CCL21, might impair recruitment of circulating fibrocytes (33) and bone marrowderived fibroblasts to injured lung (32).
The suppressive effect of PEPs-treatment on AM proliferation was mediated by NO production. In vitro, AM growth suppression was restored in presence of NO inhibitor L-NAME. In accordance with this finding, PEPs expanded from iNOS 2/2 mice could not suppress AM proliferation in vitro and failed to protect from BLM-induced injury in vivo. Interestingly, our data show that whereas normally cultured PEPs could not secrete NO, they did so when stimulated with LPS and IFN-g. This would suggest that a specific environment (e.g., inflammatory) is necessary for PEPs to exert their NO-based immunomodulatory effect. Of note, the administration of NO-producing cells, such as bone marrow-derived macrophages and bone marrow-derived dendritic cells, did not exert any protective effect, therefore emphasizing the specific role of prominin-1 1 cells. We can only speculate whether NO-producing cells other than the prominin-1 1 cells secrete proinflammatory factors that in turn compensate the potential beneficial effects of NO release. Likewise, a recent study has shown that bone marrow-derived prominin-1/CD133 1 cardiac progenitors protect from autoimmune myocarditis in mice through an NO-mediated mechanism (28) . Moreover, our data are consistent with the reported benefits of NO inhalation in other lung injury models (40) , confirming that low concentrations of NO exert a protective effect, despite the evidence that iNOS 2/2 mice are protected from BLM-induced fibrosis (50) . Collectively, these findings strongly support that NO-dependent mechanisms play a critical role in PEPs protection from BLM-induced pulmonary fibrosis. Although BLM may damage structural cells of the lungs directly, its principal mode of action in leading to IPF-like pathology seems to be via endogenous mediators of inflammation, fibrinolysis, and proliferation. Thus, the development of pulmonary fibrosis represents a well-orchestrated process involving different cells at many active sites/interfaces. Aside from AM, other cells, such as T cells, neutrophils, and natural killer cells, for example, may also contribute to the pathogenesis of IPF. Therefore, nitric oxide may not only affect AM but may also influence the pathogenic process in other ways. PEPs represent a population of prominin-1 1 bone marrowderived cells. Prominin-1 1 cells are also found in blood and bone marrow of healthy animals, but do not share analogous regenerative and immunomodulatory properties with PEPs (unpublished data). We believe that either the specific microenvironment created by disintegration of whole pulmonary tissue or inflammatory processes are critical for the activation and expansion of immunomodulatory and regenerative PEPs. Appropriate adaptation and optimization of culture conditions for blood-or bone marrow-derived cells might enable isolation and expansion of vast numbers of immunomodulatory/regenerative cells from the peripheral circulation as well. This would be a further step toward an innovative treatment strategy against inflammatory pulmonary diseases.
In conclusion, we have been successful in the expansion of a bone marrow-derived epithelial progenitor population from adult murine lungs with immunosuppressive and regenerative capacities. Our study represents an important step toward the development of novel cell-based therapies not only for IPF but also for other pulmonary disorders, such as acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, or sepsis.
